| pubmed-article:181028 | pubmed:abstractText | The coronary-active drug 3-2-diethylaminoethyl)-4-methyl-7-(carbethoxy-methoxy)-2-oxo-1,2-chromene-hydrochloride (carbocromen, Intensain) is known to be an inhibitor of phosphodiesterase (PDE). After intravenous as well as after intraduodenal application of therapeutic doses carbocromen increases in vivo the cAMP-contents of the hearts of rats (by up to 30%) and dogs (up to 50%). This effect is dose related. Correlations between the pharmacokinetic properties and metabolic actions of carbocromen and its influence on the adenylcyclase system are discussed. | lld:pubmed |
